Wall Street Zen Upgrades Zymeworks (NASDAQ:ZYME) to “Buy”

Wall Street Zen upgraded shares of Zymeworks (NASDAQ:ZYME) from a hold rating to a buy rating in a report issued on Sunday.

Zymeworks Stock Performance

NASDAQ:ZYME opened at $14.10 on Friday. Zymeworks has a one year low of $9.03 and a one year high of $17.70. The company has a market cap of $1.06 billion, a P/E ratio of -14.54 and a beta of 1.26.

Zymeworks (NASDAQ:ZYME) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.55. The company had revenue of $48.73 million during the quarter, compared to analyst estimates of $13.66 million. Zymeworks had a negative net margin of 59.96% and a negative return on equity of 21.59%.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.